- LXRP’s
patented DehydraTECH technology will be employed by each wholly owned
subsidiary, with applications applied to the industry segments
- At its
2018 Annual General and Special Meeting (AGM), all motions were passed,
including election of board members and approval of its conversion plan
- Move
to convert the company from a U.S.-based firm to Canada-based is placed on
‘indefinite hold’ due to inequitable tax treatment issue; LXRP to seek a
resolution
At Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) 2018
Annual General Meeting, all motions were passed. The company is proceeding on
schedule with its reorganization into four new wholly owned subsidiaries to
serve the nicotine, hemp, pharmaceutical and cannabis industries. All of these
subsidiaries will utilize the company’s patented DehydraTECH® proprietary
absorption technology for application to their own sectors (http://ibn.fm/U61dv). The
company said that the reorganization will assist in the growth and evolution of
each of the four subsidiaries, including, but not limited to, the areas of
research, development and finance.
Also during the annual meeting, Chris Bunka, John Docherty,
Nick Baxter and Ted McKechnie won election as directors. In addition, the
appointment of auditors was approved, as was the plan of conversion.
LXRP is a biotechnology company that out-licenses its
disruptive delivery technology that promotes healthier ingestion methods. It
results in lower dosing and higher effectiveness. LXRP holds a patent for oral
delivery of all cannabinoids. It has a growing IP portfolio and will license in
any of the 40 countries worldwide where its technology already has a patent or
is patent-pending.
It was also decided that the planned change of domicile of
LXRP from a U.S.-based company to a Canadian-based firm will be placed on
‘indefinite hold’ due to the issue of inequitable tax treatment of a certain
class of stockholders. LXRP reported that tax experts informed the company that
the move may create punitive taxes for some shareholders.
If a resolution to the tax issue is found, the plan of
conversion could take place in the future. If inequitable tax treatment cannot
be resolved, the conversion will not occur, LXRP noted.
For more information, visit the company’s website at www.LexariaBioscience.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment